Timken India Ltd Q1 FY27 Results Analysis: Revenue Surges 14.87%, EBITDA Margin Expands 94 bps

CompoundingAI Research Updated August 04, 2026 2 min read
Positive

Timken India Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 929.09 Cr (+14.87% YoY) and PAT growth of +10.46% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateAugust 04, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 929.09 Cr (+14.87% YoY)
PAT (Q1)Rs. 115.13 Cr (+10.46% YoY)
EBITDA margin18.54% (+94 bps YoY)
EPS (Q1)Rs. 15.31 (+10.46% YoY)
Market capRs. 24,324.69 Cr
CMPRs. 3,231.90

Quarter Snapshot

Revenue grew 14.87% to a record Q1 high, EBITDA margins expanded 94 bps from price pass-through and operating leverage. Depreciation from Bharuch capex and higher tax rate capped reported PAT growth at 10.46%, but normalized PAT rose 16.45%. Zero-debt balance sheet and ongoing capacity expansions (Bharuch ramp-up, Jamshedpur rail) position the company for sustained growth.

Key Investment Insights

Key Positives

  • Revenue grew 14.87% YoY to Rs.929.09 Cr, highest-ever first quarter.
  • EBITDA grew 21.01% YoY to Rs.172.24 Cr, with margin expanding 94 bps to 18.54%.
  • Normalized PAT grew 16.45% YoY to Rs.111.76 Cr.
  • Net material cost as % of revenue improved 97 bps YoY to 60.09%, indicating successful price pass-through.
  • Zero-debt balance sheet with cash equivalents of Rs.268.5 Cr provides ample liquidity.
  • Consolidated PAT includes Rs.4.53 Cr from subsidiary, which is profitable.

Risk Factors

  • Depreciation surged 50.62% YoY to Rs.31.33 Cr due to Bharuch plant capitalisation, limiting PAT growth to 10.46% vs EBITDA growth of 21.01%.
  • Effective tax rate jumped 333 bps YoY to 23.42%, reducing net profit growth.
  • Other expenses grew 15.47% YoY, in line with revenue, indicating ongoing ramp-up costs from Bharuch.
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now